-
IMPORTANT: In the next few weeks, we will be upgrading the message board software. We expect minimal downtime during the upgrade, and we will attempt to complete this during low-traffic hours. We will post an exact time several days ahead of the switch.Dismiss Notice
In preparation for the upgrade, we will be performing board maintenance, such as moving boards to Lost Civilizations where appropriate. Lost Civilizations is a category for companies that have either been dissolved or acquired. The boards serve as both an archive of the old company posts, as well as a place for former employees to reminisce or reconnect, as they will remain open for posting. We may also remove some board threads that have been inactive for several years.
Recent Posts
-
Serious question
AZ can price it as a generic in 2025. And they can take the whole market in one swipe.
-
$40.84....when will it go below $40
Shorts are doing well with BMY. Should go below $40 this week. Next support at $35. Unless Sotyktu has a huge surprise jump in sales or massive layoffs begin immediately this dog is poised to break below $30 within 3 months. Hang on for the...
-
Sang
Anyone considering working in DSI oncology let this thread demonstrate the chauvinistic west coast pigs treatment of women at this organization. An example of old school pharma judging women by their looks, insulting each other, patting each...
-
-
America's doctors need more obesity medicine training
via The relatively small number of health care providers trained in obesity care can hardly keep up with Americans' demand for new weight-loss drugs. Why it matters: Tens of thousands of U.S. patients each week are starting on treatments like...
-
Novartis Eyes Rare Kidney Disease Approvals on Heels of Two Phase III Wins
via Novartis on Saturday posted two promising Phase III readouts in rare kidney diseases, setting the pharma up for two potential approvals in the space. The company presented these data at the European Renal Association Congress over the...
-
BioNTech pays $25M upfront to strengthen ADC bond with China's MediLink
via After penning a couple of antibody-drug conjugate (ADC) deals in 2023, BioNTech has returned to MediLink Therapeutics to further pad out its portfolio. This time, BioNTech is handing over $25 million upfront for the chance to apply...
- + Show More
-
General Discussion
Discussion boards of general interest for those in the pharma, biotech, medical device, and related industries
-
Pharma/Biotech Companies
Anonymous discussion boards for pharmaceutical and biotech companies
-
Regional Discussion and Job Opportunities
Discussion and job opportunities by region
-
Lost Civilizations
Anonymous discussion boards for pharma/medical companies that no longer exist due to acquisition or other factors
-
Laboratory/Diagnostic Sales
Anonymous discussion boards for lab sales/diagnostics companies
-
Animal Health Sales
Anonymous discussion boards for animal health companies
-
Medical Equipment/Device Sales
Anonymous discussion boards for medical equipment/device companies
-
Pharmacies
Anonymous boards for pharmacy employees
-
PBMs
Anonymous discussion boards for PBMs
-
Pharma/Healthcare Marketing Agencies
Anonymous discussion boards for pharma/healthcare marketing agencies
-
Dental Reps
Anonymous discussion boards for dental health companies
-
Managed Care Specialists
Anonymous discussion boards for managed care specialists
-
Pharma IT
Anonymous discussion boards for pharma IT employees